Worth Watching Stock: Pinnacle West Capital Corporation(NYSE:PNW): Neurocrine Biosciences, Inc.(NASDAQ:NBIX)

0
4

Pinnacle West Capital Corporation (PNW) will report its next earnings on Feb 22 BMO. The company reported the earnings of $0.23/Share in the last quarter where the estimated EPS by analysts was $0.18/share. The difference between the expected and actual EPS was $0.05/share, which represents an Earnings surprise of 27.8%.

Many analysts are providing their Estimated Earnings analysis for Pinnacle West Capital Corporation and for the current quarter 9 analysts have projected that the stock could give an Average Earnings estimate of $0.1/share. These analysts have also projected a Low Estimate of $0.03/share and a High Estimate of $0.17/share.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Pinnacle West Capital Corporation as 711.86 Million. According to these analysts, the Low Revenue Estimate for Pinnacle West Capital Corporation is 686.23 Million and the High Revenue Estimate is 740.34 Million. The company had Year Ago Sales of 692.71 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for PNW to be 300%. They are projecting Next Quarter growth of 3.38%. For the next 5 years, Pinnacle West Capital Corporation is expecting Growth of 4.12% per annum, whereas in the past 5 years the growth was 6.83% per annum.

Some buy side analysts are also providing their Analysis on Pinnacle West Capital Corporation, where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 3 said it’s a HOLD, and 1 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Pinnacle West Capital Corporation might touch $100 high while the Average Price Target and Low price Target is $93.67 and $87 respectively.

Pinnacle West Capital Corporation closed its last trading session at $95.38 with the loss of -0.24%. The Market Capitalization of the company stands at 10.68 Billion. The Company has 52-week high of $95.62 and 52-week low of $73.41. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 2.85% where SMA50 and SMA200 are 7.11% and 13.44% respectively. The Company Touched its 52-Week High on 03/14/19 and 52-Week Low on 06/11/18.

The Relative Volume of the company is 0.83 and Average Volume (3 months) is 1.16 million. The company’s P/E (price to earnings) ratio is 21.23 and Forward P/E ratio of 18.79.

The company shows its Return on Assets (ROA) value of 2.9%. The Return on Equity (ROE) value stands at 9.9%. While it’s Return on Investment (ROI) value is 6.1%.

While looking at the Stock’s Performance, Pinnacle West Capital Corporation currently shows a Weekly Performance of 2.59%, where Monthly Performance is 5.99%, Quarterly performance is 3.81%, 6 Months performance is 19.4% and yearly performance percentage is 24.51%. Year to Date performance value (YTD perf) value is 11.68%. The Stock currently has a Weekly Volatility of 1.02% and Monthly Volatility of 1.31%.

Neurocrine Biosciences, Inc. (NBIX) will report its next earnings on Feb 05 AMC. The company reported the earnings of $0.19/Share in the last quarter where the estimated EPS by analysts was $0.18/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 5.6%.

Many analysts are providing their Estimated Earnings analysis for Neurocrine Biosciences, Inc. and for the current quarter 14 analysts have projected that the stock could give an Average Earnings estimate of $-0.85/share. These analysts have also projected a Low Estimate of $-1.4/share and a High Estimate of $0.09/share.

In case of Revenue Estimates, 13 analysts have provided their consensus Average Revenue Estimates for Neurocrine Biosciences, Inc. as 136.72 Million. According to these analysts, the Low Revenue Estimate for Neurocrine Biosciences, Inc. is 127.1 Million and the High Revenue Estimate is 143.5 Million. The company had Year Ago Sales of 71.09 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for NBIX to be -95.7%. They are projecting Next Quarter growth of 500%. For the next 5 years, Neurocrine Biosciences, Inc. is expecting Growth of 2703.32% per annum, whereas in the past 5 years the growth was -50% per annum.

Some buy side analysts are also providing their Analysis on Neurocrine Biosciences, Inc., where 4 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Neurocrine Biosciences, Inc. might touch $127 high while the Average Price Target and Low price Target is $106.6 and $87 respectively.

Neurocrine Biosciences, Inc. closed its last trading session at $83.93 with the loss of -1.14%. The Market Capitalization of the company stands at 7.56 Billion. The Company has 52-week high of $126.98 and 52-week low of $64.72. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 3.88% where SMA50 and SMA200 are 0.22% and -15.93% respectively. The Company Touched its 52-Week High on 09/13/18 and 52-Week Low on 12/12/18.

The Relative Volume of the company is 0.44 and Average Volume (3 months) is 1.02 million. The company’s P/E (price to earnings) ratio is 458.4 and Forward P/E ratio of 30.81.

The company shows its Return on Assets (ROA) value of 2.4%. The Return on Equity (ROE) value stands at 5.1%. While it’s Return on Investment (ROI) value is 4.2%.

While looking at the Stock’s Performance, Neurocrine Biosciences, Inc. currently shows a Weekly Performance of 7.67%, where Monthly Performance is -1.89%, Quarterly performance is -3.25%, 6 Months performance is -31.9% and yearly performance percentage is -8.18%. Year to Date performance value (YTD perf) value is 16.19%. The Stock currently has a Weekly Volatility of 3.17% and Monthly Volatility of 3.25%.

SHARE